Wapnick Pamela's Form 4 filing
Metagenomi Therapeutics, Inc. (MGX) · filed Dec 1, 2025
- Accession no.
- 0001193125-25-304218
- Filed
- Dec 1, 2025
- Trade date
- Sep 5-Dec 1, 2025
- Filing delay
- 87 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $2.85K. It was filed 87 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Wapnick PamelaCIK 0001995657 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 5, 2025 | Common Stock | SSaleDisposed | −1,576 | $1.81 | −$2,852.56 | 70,532 | Direct | |
| Dec 1, 2025 | Common Stock | AGrant or awardAcquired | +120,000 | $1.60 | +$192,000 | 190,532 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.